secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040949
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q2 net loss $9.6M; cash $71.4M; raises up to $185M
-----------------------------------------------------------------

- Net loss of $9.6M ($0.40 per share) in Q2 2023 vs $9.2M ($0.65 per share) in Q2 2022.
- Cash and short-term investments totaled $71.4M at June 30, 2023, up from $56.4M at Dec 31, 2022.
- Closed financing worth up to $185M, including $35M upfront, to fund through Phase 2 BESTOW trial.
- Ninth patient dosed in Phase 1b kidney transplant trial; updated data expected Q4 2023.
- Preclinical study shows subcutaneous tegoprubart formulation safe with similar blood levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023040949/0000950170-23-040949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023040949/eldn-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer